| Arbutus Biopharma is a therapeutic solutions company focused on discovering, developing, and commercializing a cure for patients with chronic hepatitis B infection, a disease of the liver caused by the hepatitis B virus (HBV). Co. is developing a product pipeline consisting of multiple drug candidates with complementary mechanisms of action. In addition to its drug pipeline focused on HBV, Co. has royalty entitlement on Onpattro, a drug that incorporates its lipid nanoparticle delivery technology. Co. also has interest in Genevant Sciences Ltd. to which Co. has licensed its lipid nanoparticle delivery platform and conjugate delivery platform for all applications except HBV. We show 35 historical shares outstanding datapoints in our coverage of ABUS's shares outstanding history.|
Understanding the changing numbers of ABUS shares outstanding — and
comprehending the concept of differing number of shares outstanding in general comparing companies like ABUS versus peers —
is critical for investors. Many "beginner" or "novice" investors will look at one stock trading at a price of $10 per share and another trading at
a price of $20 per share and think the latter company is worth twice as much. Of course, that is a completely meaningless comparison without also knowing how many shares outstanding there are for each of the two companies.
Furthermore, via issuance of new shares over time, or the repurchase of existing shares, the number of shares outstanding can fluctuate over the course of history.
With this page we aim to empower investors researching ABUS by allowing them to research ABUS shares outstanding history
as well as any other stock in our coverage universe.